Participating Faculty

Published on: 
Supplements and Featured Publications, Emerging Trends and Formulary Considerations for Atypical Antipsychotics, Volume 11, Issue 8 Suppl

The American Journal of Managed Care

This supplement to contains information on atypical antipsychotics and their cost effectiveness in the treatment of schizophrenia and bipolar disease.


David J. Harrison, PhDSenior Manager

Pfizer Inc

Senior Director

New York, NY

Amie T. Joyce, MPH

PharMetrics, Inc

Medical Director

New York, NY

Michael B. Lustik, MS

Science Applications International Corporation


New York, NY

Daniel A. Ollendorf, MPH

Analytic & Consulting Services

Watertown, MA

George M. Simpson, MD


Department of Psychiatry and the Behavioral Sciences

Los Angeles, CA

Richard C. Surles, PhD

Comprehensive NeuroScience, Inc

Senior Statistician

Reston, VA

Disclosure Statement

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following participants have declared the following affiliations with corporate organizations:

  • David J. Harrison, PhD Employee: Pfizer Inc

Robin P. Hertz, PhD


  • Pfizer Inc
  • Amie T. Joyce, MPH Research Support: Pfizer Inc

Antony D. Loebel, MD


  • Pfizer Inc
  • Michael B. Lustik, MS Contractor: Pfizer Inc

Margaret McDonald, PhD


  • Pfizer Inc
  • Daniel A. Ollendorf, MPH Research Support: Pfizer Inc

George M. Simpson, MD


  • Pfizer

Research Support:

  • AstraZeneca
  • Janssen Pfizer

Richard C. Surles, PhD


  • Eli Lilly and Company
  • Alan N. Unger, PhD Contractor: Pfizer Inc

The American Journal of Managed Care,

Signed disclosures are on file at the offices of Jamesburg, New Jersey.

This supplement was funded by Pfizer Inc.


We would like to thank Laura Brasseur and Debbie Godfrey for their contributions to this supplement.

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.